It has been demonstrated that an elevated AKT activity is involved in the high rate of glucose uptake in cancer cells by GLUT-1 [16,17,18] and that treatment with an AKT-specific inhibitor caused degradation of GLUT-1 in sustained AKT-activated breast cancer cells [19]. This evidence concerns the gene SLC2A1 and breast carcinoma.